High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines

Human Molecular Genetics

Volumn 23, Issue 6, 2014, Pages 1551-1562

  Ketley, Ami ^a   Chen, Catherine Z ^b   Li, Xin ^a   Arya, Sukrat ^a   Robinson, Thelma E ^a   Granados Riveron, Javier ^a   Udosen, Inyang ^a   Morris, Glenn E ^c,d   Holt, Ian ^c,d   Furling, Denis ^e   Chaouch, Soraya ^e   Haworth, Ben ^f   Southall, Noel ^b   Shinn, Paul ^b   Zheng, Wei ^b   Austin, Christopher P ^b   Hayes, Christopher J ^a   Brook, J David ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^d KEELE UNIVERSITY   (United Kingdom)

^e INSERM   (France)

^f MOLECULAR DEVICES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE SPLICING; ANIMALS; CELL NUCLEUS; CELLS, CULTURED; CHROMOMYCIN A3; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLES; MYOTONIC DYSTROPHY; PEPTIDE LIBRARY; RNA-BINDING PROTEINS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; ZEBRAFISH;

EID: 84894303874     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt542     Document Type: Article

References (50)

1. Harper, P.S. (2001) Myotonic Dystrophy. Saunders, London, Philadelphia.
2. Machuca-Tzili, L., Brook, J.D. and Hilton-Jones, D. (2005) Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve, 32, 1-18.
3. Mahadevan, M., Tsilfidis, C., Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville, C., Narang, M., Barcelo, J., O'Hoy, K. et al. (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science, 255, 1253-1255.
4. Fu, Y.H., Pizzuti, A., Fenwick, R.G. Jr, King, J., Rajnarayan, S., Dunne, P.W., Dubel, J., Nasser, G.A., Ashizawa, T., de Jong, P. et al. (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science, 255, 1256-1258.
5. Brook, J.D., McCurrach, M.E., Harley, H.G., Buckler, A.J., Church, D., Aburatani, H., Hunter, K., Stanton, V.P., Thirion, J.P., Hudson, T. et al. (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member [published erratum appears in Cell 1992 Apr 17;69(2):385]. Cell, 68, 799-808.
6. Liquori, C.L., Ricker, K., Moseley, M.L., Jacobsen, J.F., Kress, W., Naylor, S.L., Day, J.W. and Ranum, L.P.W. (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science, 293, 864-867.
7. Hamshere, M.G., Newman, E.E., Alwazzan, M., Athwal, B.S. and Brook, J.D. (1997) Transcriptional abnormality in myotonic dystrophy affects DMPKbut not neighboring genes. Proc Natl Acad Sci USA, 94, 7394-7399.
8. Davis, B.M., McCurrach, M.E., Taneja, K.L., Singer, R.H. and Housman, D.E. (1997) Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci USA, 94, 7388-7393.
9. Taneja, K.L., McCurrach, M., Schalling, M., Housman, D. and Singer, R.H. (1995) Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol, 128, 995-1002.
10. Mankodi, A., Urbinati, C.R., Yuan, Q.P., Moxley, R.T., Sansone, V., Krym, M., Henderson, D., Schalling, M., Swanson, M.S. and Thornton, C.A. (2001) Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet, 10, 2165-2170.
11. Fardaei, M., Larkin, K., Brook, J.D. and Hamshere, M.G. (2001) In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res, 29, 2766-2771.
12. Fardaei, M., Rogers, M.T., Thorpe, H.M., Larkin, K., Hamshere, M.G., Harper, P.S. and Brook, J.D. (2002) Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet, 11, 805-814.
13. Kuyumcu-Martinez, N.M., Wang, G.S. and Cooper, T.A. (2007) Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell, 28, 68-78.
14. Philips, A.V., Timchenko, L.T. and Cooper, T.A. (1998) Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy (see comments). Science, 280, 737-741.
15. Mankodi, A., Takahashi, M.P., Jiang, H., Beck, C.L., Bowers, W.J., Moxley, R.T., Cannon, S.C. and Thornton, C.A. (2002) Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell, 10, 35-44.
16. Savkur, R.S., Philips, A.V. and Cooper, T.A. (2001) Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet, 29, 40-47.
17. Kimura, T., Nakamori, M., Lueck, J.D., Pouliquin, P., Aoike, F., Fujimura, H., Dirksen, R.T., Takahashi, M.P., Dulhunty, A.F. and Sakoda, S. (2005) Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Hum Mol Genet, 14, 2189-2200.
18. Lin, X., Miller, J.W., Mankodi, A., Kanadia, R.N., Yuan, Y., Moxley, R.T., Swanson, M.S. and Thornton, C.A. (2006) Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet, 15, 2087-2097.
19. Huichalaf, C., Sakai, K., Jin, B., Jones, K., Wang, G.L., Schoser, B., Schneider-Gold, C., Sarkar, P., Pereira-Smith, O.M., Timchenko, N. et al. (2010) Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cells. FASEB J, 24, 3706-3719.
20. Huichalaf, C., Schoser, B., Schneider-Gold, C., Jin, B., Sarkar, P. and Timchenko, L. (2009) Reduction of the rate of protein translation in patients with myotonic dystrophy 2. J Neurosci, 29, 9042-9049.
21. Stein, C.A., Hansen, J.B., Lai, J., Wu, S.J., Voskresenskiy, A., Hog, A., Worm, J., Hedtjarn, M., Souleimanian, N., Miller, P. et al. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acid Res, 38, e3.
22. Yu, Z., Teng, X. and Bonini, N.M. (2011) Triplet repeat-derived siRNAs enhance RNA-mediated toxicity in a Drosophila model for myotonic dystrophy. PLoS Genet, 7, e1001340.
23. Arambula, J.F., Ramisetty, S.R., Baranger, A.M. and Zimmerman, S.C. (2009) A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. Proc Natl Acad Sci USA, 106, 16068-16073.
24. Gareiss, P.C., Sobczak, K., McNaughton, B.R., Palde, P.B., Thornton, C.A. and Miller, B.L. (2008) Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc, 130, 16254-16261.
25. Mulders, S.A., van den Broek, W.J., Wheeler, T.M., Croes, H.J., van Kuik-Romeijn, P., de Kimpe, S.J., Furling, D., Platenburg, G.J., Gourdon, G., Thornton, C.A. et al. (2009) Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA, 106, 13915-13920.
26. Pushechnikov, A., Lee, M.M., Childs-Disney, J.L., Sobczak, K., French, J.M., Thornton, C.A. and Disney, M.D. (2009) Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc, 131, 9767-9779.
27. Warf, M.B., Nakamori, M., Matthys, C.M., Thornton, C.A. and Berglund, J.A. (2009) Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci USA, 106, 18551-18556.
28. Wheeler, T.M., Sobczak, K., Lueck, J.D., Osborne, R.J., Lin, X., Dirksen, R.T. and Thornton, C.A. (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science, 325, 336-339.
29. O'Leary, D.A., Sharif, O., Anderson, P., Tu, B., Welch, G., Zhou, Y., Caldwell, J.S., Engels, I.H. and Brinker, A. (2009) Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening. PLoS One, 4, e8348.
30. Orengo, J.P., Bundman, D. and Cooper, T.A. (2006) A bichromatic fluorescent reporter for cell-based screens of alternative splicing. Nucleic Acids Res, 34, e148.
31. Chaouch, S., Mouly, V., Goyenvalle, A., Vulin, A., Mamchaoui, K., Negroni, E., Di Santo, J., Butler-Browne, G., Torrente, Y., Garcia, L. et al. (2009) Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells. Hum Gene Ther, 20, 784-790.
32. Wang, G.S. and Cooper, T.A. (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet, 8, 749-761.
33. Savkur, R.S., Philips, A.V., Cooper, T.A., Dalton, J.C., Moseley, M.L., Ranum, L.P. and Day, J.W. (2004) Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet, 74, 1309-1313.
34. Dansithong, W., Paul, S., Comai, L. and Reddy, S. (2005) MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem, 280, 5773-5780.
35. Hino, S., Kondo, S., Sekiya, H., Saito, A., Kanemoto, S., Murakami, T., Chihara, K., Aoki, Y., Nakamori, M., Takahashi, M.P. et al. (2007) Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1. Hum Mol Genet, 16, 2834-2843.
36. Todd, P.K., Ackall, F.Y., Hur, J., Sharma, K., Paulson, H.L. and Dowling, J.J. (2013) Transcriptional changes and developmental abnormalities in a Zebrafish model of Myotonic Dystrophy Type 1. Dis Model Mech, [Epub ahead of print].
37. Wang, G.S., Kuyumcu-Martinez, M.N., Sarma, S., Mathur, N., Wehrens, X.H. and Cooper, T.A. (2009) PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest, 119, 3797-3806.
38. Disney, M.D., Lee, M.M., Pushechnikov, A. and Childs-Disney, J.L. (2010) The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophies. Chembiochem, 11, 375-382.
39. Chen, C.Z., Sobczak, K., Hoskins, J., Southall, N., Marugan, J.J., Zheng, W., Thornton, C.A. and Austin, C.P. (2012) Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal Bioanal Chem, 402, 1889-1898.
40. Garcia-Lopez, A., Llamusi, B., Orzaez, M., Perez-Paya, E. and Artero, R.D. (2011) In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc Natl Acad Sci USA, 108, 11866-11871.
41. O'Leary, D.A., Vargas, L., Sharif, O., Garcia, M.E., Sigal, Y.J., Chow, S.K., Schmedt, C., Caldwell, J.S., Brinker, A. and Engels, I.H. (2010) HTS-compatible patient-derived cell-based assay to identify small molecule modulators of aberrant splicing in myotonic dystrophy type 1. Curr Chem Genomics, 4, 9-18.
42. Sicot, G., Gourdon, G. and Gomes-Pereira, M. (2011) Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges. Hum Mol Genet, 20, R116-R123.
43. Kaziro, Y. and Kamiyama, M. (1965) Inhibition of RNA polymerase reaction by chromomycin A3. Biochem Biophys ResCommun, 19, 433-437.
44. Berman, E., Brown, S.C., James, T.L. and Shafer, R.H. (1985)NMRstudies of chromomycin A3 interaction with DNA. Biochemistry, 24, 6887-6893.
45. Chakrabarti, S., Bhattacharyya, D. and Dasgupta, D. (2000) Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), and mithramycin: roles of minor groove width and ligand flexibility. Biopolymers, 56, 85-95.
46. Hernandez-Hernandez, O., Bermudez-de-Leon, M., Gomez, P., Velazquez-Bernardino, P., Garcia-Sierra, F. and Cisneros, B. (2006) Myotonic dystrophy expanded CUG repeats disturb the expression and phosphorylation of tau in PC12 cells. J Neurosci Res, 84, 841-851.
47. Jin, J., Wang, G.L., Salisbury, E., Timchenko, L. and Timchenko, N.A. (2009) GSK3beta-cyclin D3-CUGBP1-eIF2 pathway in aging and in myotonic dystrophy. Cell Cycle, 8, 2356-2359.
48. Timchenko, N.A., Iakova, P., Cai, Z.J., Smith, J.R. and Timchenko, L.T. (2001) Molecular basis for impaired muscle differentiation in myotonic dystrophy. Mol Cell Biol, 21, 6927-6938.
49. Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.T. and Austin, C.P. (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med, 3, 80ps16.
50. Holt, I., Mittal, S., Furling, D., Butler-Browne, G.S., Brook, J.D. and Morris, G.E. (2007) Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles. Genes Cells, 12, 1035-1048.